Tryton begins trial of side branch stent
This article was originally published in Clinica
Tryton Medical, of Durham, North Carolina, has initiated a registry study of its Tryton side branch stent. Called E-Tryton 150, the study is one of four registries in Europe evaluating the Tryton device in real-world clinical settings. It will enrol 150 patients with a primary endpoint of overall rate of major adverse cardiac events (MACE) – defined as cardiac death, myocardial infarction and target lesion revascularisation (main and/or side branch) – at six months following the procedure. The study will also assess the technical and procedural success of the stent. Designed to treat bifurcated atherosclerotic lesions, the cobalt chromium Tryton side branch stent is used in conjunction with a conventional drug-eluting stent. It was CE marked in February 2008.